Ultragenyx Pharmaceutical Inc.

Performance Summary

Ultragenyx Pharmaceutical Inc. reported financial results for fiscal year 2025 ending December 31, 2025. The company generated total revenues of $673.0 million while incurring substantial operating expenses totaling $1.21 billion. This resulted in a loss from operations of $535.0 million and a net loss of $575.0 million. The net loss per share was $6.00 for both basic and diluted calculations. Research and development expenses represented the largest component of operating expenses at $750.0 million, followed by selling, general and administrative expenses of $349.0 million and cost of sales of $109.0 million. The company's financial performance reflects continued investment in research and development activities while generating revenue from product sales and other sources.

Revenue Analysis

The company reported total revenues of $673.0 million for fiscal year 2025. The document does not provide detailed segment breakdown, geographic mix, or specific growth drivers for revenue. The XBRL data shows total revenues as a consolidated figure without segmentation. No further revenue breakdown by product lines, therapeutic areas, or geographic regions is provided in the available data. The absence of segment disclosure suggests the company may operate as a single reporting segment or that segment information is not required to be disclosed based on materiality thresholds.

Margins & Profitability

The company reported a gross profit margin that can be calculated from available data. With total revenues of $673.0 million and cost of sales of $109.0 million, the gross profit was $564.0 million, representing a gross margin of approximately 83.8%. The operating margin was negative 79.5% based on loss from operations of $535.0 million relative to total revenues. The cost structure shows research and development as the largest expense category at $750.0 million, followed by selling, general and administrative expenses of $349.0 million. The company's profitability metrics reflect significant investment in research and development activities that exceed current revenue generation.

Cash Flow & Balance Sheet

The company reported net cash used in operating activities of $466.0 million for fiscal year 2025. Investing activities provided net cash of $236.0 million, primarily from proceeds from maturities of marketable securities of $444.0 million. Financing activities provided net cash of $478.0 million, mainly from proceeds from the sale of future royalties, net of $392.0 million. The balance sheet shows total assets of $1.53 billion, including cash and cash equivalents of $421.0 million and total current assets of $951.0 million. Total liabilities were $1.60 billion, resulting in stockholders' equity deficit of $80.0 million. The company maintains liquidity through cash reserves and marketable securities while utilizing financing activities to support operations.

Outlook

The document does not contain specific management guidance, strategic priorities, or forward-looking statements in the provided content. No outlook section, risk factors, or management discussion and analysis is included in the extracted data. The financial statements and XBRL data present historical financial information without projections or future expectations. Investors should refer to the complete 10-K filing for comprehensive risk factors, management discussion, and forward-looking statements that typically accompany SEC filings of this nature.